Asociace polymorfizmu NAD (P) H chininové oxidoreduktázy 1 rs1800566 s karcinomem močového měchýře a prostaty – systematický přehled a metaanalýza

Stáhnout PDF English version

Autoři: Mehdi Abedinzadeh ¹; Mansour Moghimi ²; Alireza Seyed Dastgheib ³; Hossein Maleki ¹; E. Salehi ⁴; Z. Mohammad ⁵; Hossein Mohammad Jarahzadeh ⁶; Hossein Neamatzadeh ^7,8
Působiště autorů: Department of Urology, Shahid Sadoughi University of Medical Sciences, Shahid Rahnamoun Hospital, Yazd, Iran ¹; Department of Pathology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ²; Department of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran ³; Department of Basic Science, Faculty of Veterinary Medicine, Ardakan University, Ardakan, Iran ⁴; Department of Surgery, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ⁵; Department of Anesthesiology and Critical Care, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ⁶; Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ⁷; Mother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ⁸
Vyšlo v časopise: Klin Onkol 2020; 33(2): 92-100
Kategorie: review
doi: https://doi.org/10.14735/amko202092

Souhrn

Východiska: Bylo provedeno několik studií s cílem zkoumání asociace polymorfizmu NAD (P) H chinin oxidoreduktázy 1 (NQO1) rs1800566 s rizikem karcinomu močového měchýře a prostaty, ale byly předloženy nekonzistentní výsledky. Proto jsme provedli metaanalýzu, abychom poskytli komplexní údaje o asociaci polymorfizmu NQO1 rs1800566 s karcinomem močového měchýře a prostaty.

Metody: Příslušné studie byly identifikovány v databázích PubMed, Google Scholar, EMBASE a China National Knowledge Infrastructure před 1. červnem 2019.

Výsledky: Bylo vybráno celkem 22 případových kontrolních studií zahrnujících 15 studií karcinomu močového měchýře se 4 413 případy a 4 275 kontrolami a 7 studií karcinomu prostaty s 762 případy a 1 813 kontrolami. Souhrnná data ukázala, že polymorfizmus NQO1 rs1800566 byl významně asociován se zvýšeným rizikem karcinomu močového měchýře (T vs. C: OR 1,300; 95% CI 1,112–1,518; p = 0,001; TT vs. CC: OR 1,415; 95% CI 1,084–1,847; p = 0,011; TC vs. CC: OR 1,389; 95% CI 1,111–1,738; p = 0,004; TT + TC vs. CC: OR 1,428; 95% CI 1,145–1,782; p = 0,002) a karcinomu prostaty (TC vs. CC: OR 1,276; 95% CI 1,047–1,555; p = 0,016; TT + TC vs. CC: OR 1,268; 95% CI 1,050–1,532; p = 0,014). Analýza stratifikovaná podle etnicity odhalila zvýšené riziko karcinomu močového měchýře u Kavkazanů a karcinomu prostaty u Asiatů.

Závěr: Tato metaanalýza naznačuje, že polymorfizmus NQO1 rs1800566 byl významně spojen se zvýšeným rizikem karcinomu močového měchýře a prostaty.

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Klíčová slova:

karcinom močového měchýře – karcinom prostaty – gen NQO1 – polymorfizmus – metaanalýza

Zdroje

1. Wong MC, Fung FD, Leung C et al. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep 2018; 8 (1): 1129. doi: 10.1038/s41598-018-19199-z.

2. Gunlusoy B, Ceylan Y, Degirmenci T et al. The potential effect of age on the natural behavior of bladder cancer: Does urothelial cell carcinoma progress differently in various age groups? Kaohsiung J Med Sci 2016; 32 (5): 261–266. doi: 10.1016/j.kjms.2016.03.002.

3. Sanli O, Dobruch J, Knowles MA et al. Bladder cancer. Nat Rev Dis Primers 2017; 3 : 17022. doi: 10.1038/nrdp.2017.22.

4. Bashir MN. Epidemiology of prostate cancer. Asian Pac J Cancer Prev 2015; 16 (13): 5137–5141. doi: 10.7314/apjcp.2015.16.13.5137.

5. Abedinzadeh M, Zare-Shehneh M, Neamatzadeh H et al. Association between MTHFR C677T polymorphism and risk of prostate cancer: evidence from 22 studies with 10,832 cases and 11,993 controls. Asian Pac J Cancer Prev 2015; 16 (11): 4525–4530. doi: 10.7314/apjcp.2015.16.11.4525.

6. Madersbacher S, Alcaraz A, Emberton M et al. The influence of family history on prostate cancer risk: implications for clinical management. BJU Int 2011; 107 (5): 716–721. doi: 10.1111/j.1464-410X.2010.10024.x.

7. Dudek AM, Grotenhuis AJ, Vermeulen SH et al. Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms? Int J Mol Sci 2013; 14 (6): 12346–12366. doi: 10.3390/ijms140612346.

8. Huang ZM, Chen HA, Chiang YT et al. Association of polymorphisms in iNOS and NQO1 with bladder cancer risk in cigarette smokers. J Chin Med Assoc 2014; 77 (2): 83–88. doi: 10.1016/j.jcma.2013.10.005.

9. Ergen HA, Gormus U, Narter F et al. Investigation of NAD (P) H: quinone oxidoreductase 1 (NQO1) C609T polymorphism in prostate cancer. Anticancer Res 2007; 27 (6B): 4107–4110.

10. Jaiswal AK. Human NAD (P) H: quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry 1991; 30 (44): 10647–10653. doi: 10.1021/bi00108a007.

11. Zhang Y, Yang D, Zhu JH et al. The association between NQO1 Pro187Ser polymorphism and urinary system cancer susceptibility: a meta-analysis of 22 studies. Cancer Invest 2015; 33 (2): 39–40. doi: 10.3109/07357907.2014.998836.

12. Wang XC, Wang J, Tao HH et al. Combined effects of NQO1 Pro187Ser or SULT1A1 Arg213His polymorphism and smoking on bladder cancer risk: two meta-analyses. Int J Occup Med Environ Health 2017; 30 (5): 791–802. doi: 10.13075/ijomeh.1896.00930.

13. Yadav U, Kumar P, Rai V. NQO1 gene C609T polymorphism (dbSNP: rs1800566) and digestive tract cancer risk: a meta-analysis. Nutr Cancer 2018; 70 (4): 557–568. doi: 10.1080/01635581.2018.1460674.

14. Ding R, Lin S, Chen D. Association of NQO1 rs1800566 polymorphism and the risk of colorectal cancer: a meta-analysis. Int J Colorectal Dis 2012; 27 (7): 885–892. doi: 10.1007/s00384-011-1396-0.

15. Schulz WA, Eickelmann P, Sies H. Free radicals in toxicology: redox cycling and NAD (P) H: quinone oxidoreductase. Arch Toxicol Suppl 1996; 18 : 217–222. doi: 10.1007/978-3-642-61105-6_22.

16. Pandith AA, Khan NP, Shah ZA et al. Association of bladder cancer risk with an NAD (P) H: quinone oxidoreductase polymorphism in an ethnic Kashmiri population. Biochem Genet 2011; 49 (7–8): 417–426. doi: 10.1007/s10528-011-9418-8.

17. Goerlitz D, Amr S, Dash C et al. Genetic polymorphisms in NQO1 and SOD2: interactions with smoking, schistosoma infection, and bladder cancer risk in Egypt. Urol Oncol 2014; 32 (1): 15–20. doi: 10.1016/j.urolonc.2013.06.016.

18. Mandal RK, Nissar K, Mittal RD. Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from North India. Mol Biol Rep 2012; 39 (12): 11145–11152. doi: 10.1007/s11033-012-2023-z.

19. Wang YH, Lee YH, Tseng PT et al. Human NAD (P) H: quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan. J Cancer Res Clin Oncol 2007; 134 (2): 203–209. doi: 10.1007/s00432-007-0271-4.

20. Fu J, Chen B. Relationship between genetic polymorphisms of CYP1A1, NQO1 and EPHX1 and susceptibility to bladder cancer. Chin J Cancer Prev Treat 2013; 20 (1): 10–14.

21. Park SJ, Zhao H, Spitz MR et al. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 2003; 536 (1–2): 131–137. doi: 10.1016/s1383-5718 (03) 00041-x.

22. Choi JY, Lee KM, Cho SH et al. CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics 2003; 13 (6): 349–355. doi: 10.1097/01.fpc.0000054096.48725.25.

23. Sanyal S, Festa F, Sakano S et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 2004; 25 (5): 729–734. doi: 10.1093/carcin/bgh058.

24. Hung RJ, Boffetta P, Brennan P et al. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis 2004; 25 (6): 973–978. doi: 10.1093/carcin/bgh080.

25. Moore LE, Wiencke JK, Bates MN et al. Investigation of genetic polymorphisms and smoking in a bladder cancer case-control study in Argentina. Cancer Lett 2004; 211 (2): 199–207. doi: 10.1016/j.canlet.2004.04.011.

26. Terry PD, Umbach DM, Taylor JA. No association between SOD2 or NQO1 genotypes and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 2005; 14 (3): 753–754. doi: 10.1158/1055-9965.EPI-04-0574.

27. Broberg K, Björk J, Paulsson K et al. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis 2005; 26 (7): 1263–1271. doi: 10.1093/carcin/bgi063.

28. Figueroa JD, Malats N, García-Closas M et al. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis 2008; 29 (10): 1955–1962. doi: 10.1093/carcin/bgn163.

29. Steiner M, Hillenbrand M, Borkowsi M et al. 609 C-T polymorphism in NAD (P) H: quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia. Cancer Lett 1999; 135 (1): 67–71. doi: 10.1016/s0304-3835 (98) 00269-9.

30. Hamajima N, Matsuo K, Iwata H et al. NAD (P) H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 2002; 7 (2): 103–108. doi: 10.1007/s101470200013.

31. Ergen HA, Gormus U, Narter F et al. Investigation of NAD (P) H: quinone oxidoreductase 1 (NQO1) C609T polymorphism in prostate cancer. Anticancer Res 2007; 27 (6B): 4107–4110.

32. Stoehr CG, Nolte E, Wach S et al. NAD (P) H: quinone oxidoreductase 1 (NQO1) P187S polymorphism and prostate cancer risk in caucasians. Int J Mol Sci 2012; 13 (9): 10959–10969. doi: 10.3390/ijms130910959.

33. Jing-Xian Z, Li-Ling L, Ya-Wen W. NQO1 C609T gene polymorphism associated with an increased risk of prostate cancer cognitive dysfunction. Chin J Behav Med and Brain Sci 2011; 20 (8): 698–700.

34. Steinbrecher A, Rohrmann S, Timofeeva M et al. Dietary glucosinolate intake, polymorphisms in selected biotransformation enzymes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2010; 19 (1): 135–143. doi: 10.1158/1055-9965.EPI-09-0660.

35. Zhang DH, Zhang Q, Zheng M et al. Effect of NQO1 C609T polymorphism on prostate cancer risk: a meta-analysis. Onco Targets Ther 2014; 7 : 907. doi: 10.2147/OTT.S62046.

36. Yang S, Jin T, Su HX et al. The association between NQO1 Pro187Ser polymorphism and bladder cancer susceptibility: a meta-analysis of 15 studies. PloS One 2015; 10 (1): e0116500. doi: 10.1371/journal.pone.0116500.

37. Gong M, Yi Q, Wang W. Association between NQO1 C609T polymorphism and bladder cancer susceptibility: a systemic review and meta-analysis. Tumor Biol 2013; 34 (5): 2551–2556. doi: 10.1007/s13277-013-0799-7.

38. Jafari Nedooshan J, Kargar S, Neamatzadeh H et al. Lack of association of the fat mass and obesity associated (FTO) gene rs9939609 polymorphism with breast cancer risk: a systematic review and meta-analysis based on case –⁠ control studies. Asian Pac J Cancer Prev 2017; 18 (4): 1031–1037. doi: 10.22034/APJCP.2017.18.4.1031.

39. Aslebahar F, Neamatzadeh H, Meibodi B et al. Association of tumor necrosis factor-α (TNF-α) -308G>A and -238G>A polymorphisms with recurrent pregnancy loss risk: a meta-analysis. Int J Fertil Steril 2019; 12 (4): 284–292. doi: 10.22074/ijfs.2019.5454.

40. Kamali M, Hamadani S, Neamatzadeh H et al. Association of XRCC2 rs3218536 polymorphism with susceptibility of breast and ovarian cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2017; 18 (7): 1743–1749. doi: 10.22034/APJCP.2017.18.7.1743.

41. Namazi A, Forat-Yazdi M, Jafari M et al. Association of interleukin-10 -1082 A/G (rs1800896) polymorphism with susceptibility to gastric cancer: meta-analysis of 6,101 cases and 8,557 controls. Arq Gastroenterol 2018; 55 (1): 33–40. doi: 10.1590/s0004-2803.201800000-18.

42. Moghimi M, Kargar S, Jafari MA et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with breast cancer risk: a meta-analysis. Asian Pac J Cancer Prev 2018; 19 (11): 3225–3231. doi: 10.31557/APJCP.2018.19.11.3225.

43. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (7): e1000097. doi: 10.1371/journal.pmed.1000097.